Compare Ascendis Pharma A/S (ASND) vs ProShares Ultra Bloomberg Natural Gas ETF (BOIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs ProShares Ultra Bloomberg Natural Gas ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while ProShares Ultra Bloomberg Natural Gas ETF trades at $21.85. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| ASND | BOIL | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $98.62 |
52-Week Low | $163.32 | $22.68 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BOIL trades at $22.68, down 4.22% in the past 24 hours amid a bearish technical outlook with moving averages signaling strong selling pressure. The stock recently underwent a 1:2 split on May 28, 2026. Key support lies at $21, with resistance at $25. Recent news highlights shareholder meeting results and natural gas market volatility influencing sentiment.
Outlook remains cautious due to weak technicals and external commodity pressures. Investment opportunities hinge on natural gas price rebounds, but risks include sustained bearish trends and energy market fluctuations. Investors should weigh technical recovery signals against fundamental exposure to volatile energy sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →
